Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
93 studies found for:    hemophilia | Open Studies
Show Display Options
Rank Status Study
21 Recruiting Hemophilia B Gene Therapy - Spark
Condition: Hemophilia B
Intervention: Biological: AAV8-hFIX19
22 Recruiting A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients With Inhibitors to Factor VIII or IX
Conditions: Hemophilia A With Inhibitors;   Hemophilia B With Inhibitors
Intervention: Biological: Coagulation Factor VIIa (Recombinant)
23 Recruiting Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery
Condition: Hemophilia A
Intervention: Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)
24 Recruiting Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)
Condition: Acquired Haemophilia
Interventions: Drug: Steroid + cyclophosphamide;   Drug: Steroid + rituximab
25 Recruiting Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A
Condition: Severe Hemophilia A
Intervention: Drug: Alphanate SD/HT
26 Recruiting ADVATE Hemophilia A Outcome Database (AHEAD)
Condition: Hemophilia A
Intervention: Biological: Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method
27 Not yet recruiting Individualized Prophylaxis for Severe Hemophilia A Children
Condition: Hemophilia
Intervention: Other: according to the efficacy of AJBRs
28 Recruiting An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Untreated Males With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: BIIB031 (rFVIIIFc)
29 Not yet recruiting Study of Recombinant Factor IX Product, IB1001, in Previously Treated Subjects With Hemophilia B
Condition: Hemophilia B
Intervention: Biological: IB1001
30 Recruiting Subclinical Joint Bleeding in Irish Adults With Severe Haemophilia A on Personalised Prophylaxis Regimens
Condition: Severe Haemophilia A
Intervention: Drug: ADVATE [Antihemophilic Factor (Recombinant)]
31 Unknown  Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Condition: Hemophilia A
Intervention:
32 Not yet recruiting Prospective Biomarkers of Bone Metabolism in Hemophilia A
Conditions: Hemophilia;   Bone Disease
Intervention: Drug: Advate
33 Recruiting Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients
Condition: Hemophilia A
Interventions: Biological: Moroctocog alfa ( AF-CC);   Procedure: Laboratory tests
34 Unknown  Quality of Life in Adult Patients With Severe Haemophilia in Turkey
Condition: Haemophilia
Intervention:
35 Recruiting Phenotypic Heterogeneity in Hemophilia A: An Investigation of the Role of Platelet Function
Condition: Hemophilia A
Intervention:
36 Recruiting Use of a TGA and TEM in the Assessment of the Efficacy of Treatment With APCC or rFVIIa
Condition: Haemophilia
Intervention:
37 Recruiting Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors
Condition: Severe Hemophilia A With Inhibitor
Intervention: Other: TGA (Thrombin generation Assay)
38 Recruiting Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Condition: Hemophilia A
Interventions: Biological: GreenGene™ F and an approved recombinant Factor VIII product;   Biological: GreenGene™ F
39 Recruiting Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS
Conditions: Hemophilia A;   Hemophilia B
Interventions: Biological: ADVATE (Antihemophilic Factor [Recombinant]);   Biological: RIXUBIS (Coagulation Factor IX [Recombinant])
40 Recruiting Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
Condition: Haemophilia A
Intervention: Biological: Optivate 500IU

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years